Literature DB >> 26599348

Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery.

Tjerk Bueters1, Christopher Gibson1, Sandra A G Visser2.   

Abstract

In this perspective article, we explain how quantitative and translational pharmacology, when well-implemented, is believed to lead to improved clinical candidates and drug targets that are differentiated from current treatment options. Quantitative and translational pharmacology aims to build and continuously improve the quantitative relationship between drug exposure, target engagement, efficacy, safety and its interspecies relationship at every phase of drug discovery. Drug hunters should consider and apply these concepts to develop compounds with a higher probability of interrogating the clinical biological hypothesis. We offer different approaches to set an initial effective concentration or pharmacokinetic-pharmacodynamic target in man and to predict human pharmacokinetics that determine together the predicted human dose and dose schedule. All concepts are illustrated with ample literature examples.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26599348     DOI: 10.4155/fmc.15.143

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  6 in total

Review 1.  Avibactam Pharmacokinetic/Pharmacodynamic Targets.

Authors:  Wright W Nichols; Paul Newell; Ian A Critchley; Todd Riccobene; Shampa Das
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 2.  Leveraging model-informed approaches for drug discovery and development in the cardiovascular space.

Authors:  Marissa F Dockendorf; Ryan C Vargo; Ferdous Gheyas; Anne S Y Chain; Manash S Chatterjee; Larissa A Wenning
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-01-20       Impact factor: 2.745

3.  Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate.

Authors:  Jeanine E Ballard; Parul Pall; Joshua Vardigan; Fuqiang Zhao; Marie A Holahan; Richard Kraus; Yuxing Li; Darrell Henze; Andrea Houghton; Christopher S Burgey; Christopher Gibson
Journal:  Pharm Res       Date:  2020-09-04       Impact factor: 4.200

4.  Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose.

Authors:  Jeanine E Ballard; Parul S Pall; Joshua Vardigan; Fuqiang Zhao; Marie A Holahan; Xiaoping Zhou; Nina Jochnowitz; Richard L Kraus; Rebecca M Klein; Darrell A Henze; Andrea K Houghton; Christopher S Burgey; Christopher Gibson; Arie Struyk
Journal:  Front Pharmacol       Date:  2021-12-24       Impact factor: 5.810

5.  Phosphorylation of extracellular signal-regulated kinase as a biomarker for cannabinoid receptor 2 activation.

Authors:  Jingru Wang; Juehua Xu; Yanyan Peng; Yue Xiao; Huang Zhu; Zhi-Ming Ding; Haiqing Hua
Journal:  Heliyon       Date:  2018-11-07

6.  Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin.

Authors:  Tomás Sou; Jon Hansen; Edgars Liepinsh; Maria Backlund; Onur Ercan; Solveiga Grinberga; Sha Cao; Paraskevi Giachou; Anna Petersson; Magdalena Tomczak; Malgorzata Urbas; Dorota Zabicka; Carina Vingsbo Lundberg; Diarmaid Hughes; Sven N Hobbie; Lena E Friberg
Journal:  Clin Pharmacol Ther       Date:  2020-11-28       Impact factor: 6.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.